OFSEP High Definition Cohort (NCT03603457)
🩺 Plain-English Summary (8th-Grade Level)
For neurologists and patients, it appears that one major unmet need, beside of course a cure to multiple sclerosis (MS), is to better appreciate the causal factors of disease progression, and even to obtain reliable predictive tools that could apply on the individual level and at different key moments in the disease course. The overarching objective of the OFSEP-HD cohort is to determine prognostic factors of the evolution of disability in MS in real life, looking at disease characteristics, care practices potentially modifying the evolution of the disease since MS clinical onset and along specific post-onset landmarks. This general framework leads to study 3 specific research objectives: 1. To identify determinants (socio-demographic characteristics, clinical characteristics, health related quality of life (QoL), changes in classification, and biomarkers) for the progression of MS disease and its consequences; 2. To study the effectiveness of treatments in real life; 3. To merge both determinants and treatments for creating patient-centered prognostic tools for identifying specific subgroups of patients and helping making decision to start, maintain or adapt care management. To achieve these objectives, the OFSEP (The French multiple sclerosis registry) infrastructure, managed under a quality insurance system, offers a unique opportunity for the first time in France to create a large cohort of MS cases, providing high-definition and sequential multimodal data.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (0 items).
Location: CHU de Besançon — Besançon
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (25 Sites)
- CHU de Besançon — Besançon,
- CHU de Bordeaux — Bordeaux,
- CHU de Caen — Caen,
- CHU de Clermont-Ferrand — Clermont-Ferrand,
- CHU de Créteil — Créteil,
- CHU de Dijon — Dijon,
- CHU de Grenoble — Grenoble,
- CHU de Lille — Lille,
- CHU de Limoges — Limoges,
- CHU de Lyon — Lyon,
- CHU de Montpellier — Montpellier,
- CHU de Nancy — Nancy,
- CHU de Nantes — Nantes,
- CHU de Nice — Nice,
- CHU de Nîmes — Nîmes,
- CHU Pitié-Salpétrière — Paris,
- CHU Saint-Antoine — Paris,
- Fondation Rothschild — Paris,
- CHI de Poissy-Saint-Germain-en-Laye — Poissy,
- CHU de Poitiers — Poitiers,
- CHU de Rennes — Rennes,
- CHU de Strasbourg — Strasbourg,
- CHU de Toulouse — Toulouse,
- CHU de Tours — Tours,
- CHU de Fort-de-France — Fort-de-France,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.